ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.
What's New
A gut-restricted bitter taste receptor agonist (ARD-101) was associated with modest weight loss and reduced hunger in adults with obesity over 28 days.
Detailed Summary
Preclinical and clinical studies evaluated denatonium acetate (ARD-101), a gut-restricted TAS2R agonist. In a randomized, placebo-controlled trial, adults with obesity taking 200 mg twice daily lost 0.8 kg more than placebo at day 28 and 1.3 kg more at end-of-study, with decreased hunger and food cravings. In DIO mice, the combination of DA with a DPP-4 inhibitor reduced body weight by 18.8%.
Study Population
Adults with obesity (clinical trial) and healthy participants (single-dose study); diet-induced obesity mouse models (preclinical)
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Discussion
Loading comments...
Comments are public. Be respectful and remember: this is not medical advice. Do not share personal health information.